Mercer Global Advisors
RARE icon

Mercer Global Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mercer Global Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Buy
71,092
+37,307
+110% +$927K ﹤0.01% 1229
2026
Q1 		$708K Buy
33,785
+19,820
+142% +$446K ﹤0.01% 1757
2025
Q4 		$321K Buy
13,965
+2,036
+17% +$67K ﹤0.01% 2180
2025
Q3 		$359K Buy
+11,929
New +$358K ﹤0.01% 1967

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Mercer Global Advisors's RARE Position: Q2 2026 in Review

Mercer Global Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 110% in Q2 2026, buying an estimated $927K and bringing the position to 71,092 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Mercer Global Advisors first reported a position in RARE in Q3 2025 and has held it in 4 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Mercer Global Advisors held 71,092 shares of Ultragenyx Pharmaceutical worth $2.37M as of Q2 2026.
  • Mercer Global Advisors bought 37,307 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $927K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1229 holding.
  • Mercer Global Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.